38.64
2.20%
+0.83
After Hours:
38.64
Halozyme Therapeutics Inc. stock is currently priced at $38.64, with a 24-hour trading volume of 1.06M.
It has seen a +2.20% increased in the last 24 hours and a -5.32% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $37.98 pivot point. If it approaches the $38.66 resistance level, significant changes may occur.
Halozyme Therapeutics Inc. Stock (HALO) Financials Data
Halozyme Therapeutics Inc. (HALO) Revenue 2024
HALO reported a revenue (TTM) of $829.25 million for the quarter ending December 31, 2023, a +25.62% rise year-over-year.
Halozyme Therapeutics Inc. (HALO) Net Income 2024
HALO net income (TTM) was $281.59 million for the quarter ending December 31, 2023, a +39.31% increase year-over-year.
Halozyme Therapeutics Inc. (HALO) Cash Flow 2024
HALO recorded a free cash flow (TTM) of $373.28 million for the quarter ending December 31, 2023, a +58.64% increase year-over-year.
Halozyme Therapeutics Inc. (HALO) Earnings per Share 2024
HALO earnings per share (TTM) was $2.11 for the quarter ending December 31, 2023, a +45.52% growth year-over-year.
Halozyme Therapeutics Inc. Stock (HALO) Latest News
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Zacks Investment Research
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
9 Analysts Have This To Say About Halozyme Therapeutics
Benzinga
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Benzinga
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Zacks Investment Research
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
Zacks Investment Research
About Halozyme Therapeutics Inc.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):